{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T22:28:20Z","timestamp":1794868100695,"version":"4.9.1"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:sec id=\"ab-eoi260012-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Among patients receiving ongoing intravitreal anti\u2013vascular endothelial growth factor (anti-VEGF) therapy who experience stroke or myocardial infarction (MI), evidence is limited on the systemic safety of continuing injections and whether treatment should be paused or modified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260012-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate whether, among patients receiving intravitreal anti-VEGF therapy who experience cardiovascular events (CVE), there exist associations between anti-VEGF treatments administered shortly before or after CVE (peri-CVE) and mortality or major functional outcomes, and to evaluate whether systemic outcomes differ by anti-VEGF agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260012-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This was a retrospective cohort study of TriNetX network deidentified electronic health records (EHR) from 2005 to 2025. This study setting was a multicenter, EHR-based network analysis including individuals with stroke or MI with established anti-VEGF history (\u22653 months pre-CVE), matched between those receiving 1 or more anti-VEGF injections within 14 days before or up to 6 weeks after CVE and those with no anti-VEGF from 3 months before to 3 months after. Propensity score matching (PSM) balanced demographics, comorbidities, procedures, systemic medications, laboratory values, and anti-VEGF agent history.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260012-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>Exposures included intravitreal anti-VEGF during the peri-CVE window vs no peri-CVE anti-VEGF. Sensitivity analyses restricted exposure to 14 days or fewer pre-CVE and compared aflibercept, bevacizumab, or ranibizumab with other agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260012-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcomes were 3-month and 1-year all-cause mortality, poststroke neurologic deficits, and post-MI heart failure. Data were expressed in relative risks (RRs) with 95% CIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260012-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 6073 and 5381 individuals with stroke or MI, respectively, were included before PSM. After PSM (1526 pairs with stroke; exposure [received peristroke anti-VEGF], mean [SD] age, 72.1 [12.9] years; 822 female [53.9%]; control [did not receive peristroke anti-VEGF], 72.7 [13.3] years; 840 female [55.0%]; and 1523 pairs with MI, exposure [received peri-MI anti-VEGF], 71.4 [13.5] years; 809 male [53.1%]; control [did not receive peri-MI anti-VEGF], 71.5 [13.3] years; 798 male [52.4%]), peristroke anti-VEGF was associated with lower mortality at 3 months (RR, 0.39; 95% CI, 0.29-0.53) and 1 year (RR, 0.52; 95% CI, 0.43-0.63) and fewer neurologic deficits at 3 months (RR, 0.64; 95% CI, 0.46-0.89) but not 1 year (RR, 0.79; 95% CI, 0.62-1.01). Peri-MI exposure was associated with lower mortality at 3 months (RR, 0.34; 95% CI, 0.26-0.43) and 1 year (RR, 0.58; 95% CI, 0.49-0.68) and lower heart failure at 3 months (RR, 0.65; 95% CI, 0.46-0.93) but not 1 year (RR, 0.87; 95% CI, 0.68-1.11). Timing-restricted analyses showed similar mortality findings without differences in neurologic deficits or heart failure. In agent-specific comparisons, there were no differences across aflibercept, bevacizumab, or ranibizumab for any outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260012-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Results of this cohort study reveal that peri-CVE anti-VEGF was not associated with increased mortality or morbidity. Outcomes did not differ among commonly used agents, supporting the safety of continuing intravitreal anti-VEGF therapy without modification during the peri-CVE period.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2026.0460","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T15:30:40Z","timestamp":1774539040000},"page":"415","source":"Crossref","is-referenced-by-count":3,"title":["Peri-Event Intravitreal Anti-VEGF and Systemic Outcomes After Stroke or Myocardial Infarction"],"prefix":"10.1001","volume":"144","author":[{"given":"Darius D.","family":"Bordbar","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali O.","family":"Mukhtar","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, Texas"},{"name":"Blanton Eye Institute, Houston Methodist Hospital, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad","family":"Loya","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants, Royal Oak, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer F.","family":"Alsoudi","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants, Royal Oak, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawad","family":"Muayad","sequence":"additional","affiliation":[{"name":"College of Medicine, Texas A&M University, Bryan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Z.","family":"Chauhan","sequence":"additional","affiliation":[{"name":"Bernice and Harvey Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimesh A.","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston"},{"name":"Department of Ophthalmology, Boston Children\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed B.","family":"Sallam","sequence":"additional","affiliation":[{"name":"Bernice and Harvey Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina Y.","family":"Weng","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"eoi260012r1","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.ophtha.2020.12.019","article-title":"Severity of diabetic retinopathy and the risk of future cerebrovascular disease, cardiovascular disease, and all-cause mortality.","volume":"128","author":"Modjtahedi","year":"2021","journal-title":"Ophthalmology"},{"issue":"3","key":"eoi260012r2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089600","article-title":"Age-related macular degeneration and the incidence of cardiovascular disease: a systematic review and meta-analysis.","volume":"9","author":"Wu","year":"2014","journal-title":"PLoS One"},{"key":"eoi260012r3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ajo.2023.08.022","article-title":"Risk of stroke, myocardial infarction, deep vein thrombosis, pulmonary embolism, and death after retinal vein occlusion.","volume":"257","author":"Wai","year":"2024","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"eoi260012r4","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ophtha.2008.09.046","article-title":"Cerebrovascular accidents in ranibizumab.","volume":"116","author":"Ueta","year":"2009","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi260012r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.09.019","article-title":"Safety in aflibercept vs ranibizumab.","volume":"121","author":"Ueta","year":"2014","journal-title":"Ophthalmology"},{"issue":"9","key":"eoi260012r6","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1016\/j.ophtha.2010.05.005","article-title":"Ranibizumab and stroke.","volume":"117","author":"Ueta","year":"2010","journal-title":"Ophthalmology"},{"issue":"12","key":"eoi260012r7","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","article-title":"Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD.","volume":"98","author":"Avery","year":"2014","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"eoi260012r8","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab.","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"issue":"5","key":"eoi260012r9","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3390\/biomedicines12051055","article-title":"Vascular endothelial growth factor (VEGF) and its role in the cardiovascular system.","volume":"12","author":"Florek","year":"2024","journal-title":"Biomedicines"},{"issue":"4","key":"eoi260012r10","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1134\/S1819712423040141","article-title":"The role of VEGF in angiogenesis and motor recovery after ischemic stroke.","volume":"17","author":"Kucherova","year":"2024","journal-title":"Neurochem J"},{"issue":"4","key":"eoi260012r11","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s12975-019-00747-2","article-title":"Association of high serum levels of growth factors with good outcome in ischemic stroke: a multicenter study.","volume":"11","author":"Sobrino","year":"2020","journal-title":"Transl Stroke Res"},{"key":"eoi260012r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2020.106060","article-title":"Serum vascular endothelial growth factor as a biomarker for prognosis of minor ischemic stroke.","volume":"196","author":"Zhang","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"issue":"6","key":"eoi260012r13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaophthalmol.2021.0640","article-title":"Cardiovascular adverse events with intravitreal anti\u2013vascular endothelial growth factor drugs: a systematic review and meta-analysis of randomized clinical trials.","volume":"139","author":"Ngo Ntjam","year":"2021","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"eoi260012r14","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1093\/ndt\/gfac305","article-title":"A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes.","volume":"38","author":"Lees","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"eoi260012r15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jamaophthalmol.2019.4636","article-title":"Risk of death associated with intravitreal anti-vascular endothelial growth factor therapy: a systematic review and meta-analysis.","volume":"138","author":"Reibaldi","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"eoi260012r16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaophthalmol.2018.0002","article-title":"Overview of systematic reviews and meta-analyses on systemic adverse events associated with intravitreal anti\u2013vascular endothelial growth factor medication use.","volume":"136","author":"Thulliez","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"eoi260012r17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1001\/jamaophthalmol.2015.4070","article-title":"Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis.","volume":"134","author":"Avery","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"eoi260012r18","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40123-021-00451-1","article-title":"Risk of myocardial infarction, stroke, or death in new users of intravitreal aflibercept vs ranibizumab: a nationwide cohort study.","volume":"11","author":"Billioti de Gage","year":"2022","journal-title":"Ophthalmol Ther"},{"issue":"3","key":"eoi260012r19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.ophtha.2020.07.062","article-title":"Risk of systemic adverse events after intravitreal bevacizumab, ranibizumab, and aflibercept in routine clinical practice.","volume":"128","author":"Maloney","year":"2021","journal-title":"Ophthalmology"},{"issue":"5","key":"eoi260012r20","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1001\/jamaophthalmol.2018.6891","article-title":"Association of intravitreal anti\u2013vascular endothelial growth factor therapy with risk of stroke, myocardial infarction, and death in patients with exudative age-related macular degeneration.","volume":"137","author":"Dalvin","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"eoi260012r21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ophtha.2024.07.008","article-title":"Cardiovascular and cerebrovascular adverse events associated with intravitreal anti-VEGF monoclonal antibodies: a World Health Organization pharmacovigilance study.","volume":"132","author":"Yang","year":"2025","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi260012r22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/aos.17534","article-title":"Intravitreal anti-vascular endothelial growth factor injections and risks of stroke in patients with neovascular age-related macular degeneration: a registry-based cohort study.","volume":"104","author":"Falemban","year":"2026","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"eoi260012r23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41433-021-01416-1","article-title":"Increased mortality after intravitreal injections of anti-VEGF for neovascular AMD among patients with prior stroke or acute myocardial infarction.","volume":"36","author":"Chen","year":"2022","journal-title":"Eye (Lond)"},{"issue":"4","key":"eoi260012r24","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00417-018-3917-9","article-title":"Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis.","volume":"256","author":"Hanhart","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"eoi260012r25","doi-asserted-by":"publisher","first-page":"e732","DOI":"10.1111\/aos.13731","article-title":"Mortality after a cerebrovascular event in age-related macular degeneration patients treated with bevacizumab ocular injections.","volume":"96","author":"Hanhart","year":"2018","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"eoi260012r26","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1177\/24741264211028441","article-title":"Intravitreal injection therapy: current techniques and supplemental services.","volume":"5","author":"Lam","year":"2021","journal-title":"J Vitreoretin Dis"},{"issue":"0","key":"eoi260012r27","doi-asserted-by":"publisher","DOI":"10.21037\/aes-24-27","article-title":"A narrative review of TriNetX in ophthalmology: applications, advantages, and pitfalls.","volume":"9","author":"Hackl","year":"2024","journal-title":"Ann Eye Sci"},{"issue":"1","key":"eoi260012r29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jcjo.2024.05.013","article-title":"Cardiovascular risk in anti-VEGF treatment of neovascular age-related macular degeneration.","volume":"60","author":"Chong","year":"2025","journal-title":"Can J Ophthalmol"},{"issue":"10","key":"eoi260012r30","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3928\/23258160-20250702-01","article-title":"Estimated 5-year risk of systemic cardiovascular events with anti-VEGF injections in neovascular age-related macular degeneration.","volume":"56","author":"Chong","year":"2025","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"4","key":"eoi260012r31","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000323943","article-title":"Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab.","volume":"225","author":"Carneiro","year":"2011","journal-title":"Ophthalmologica"},{"issue":"3","key":"eoi260012r32","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jcjo.2012.03.026","article-title":"Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections.","volume":"47","author":"Sharma","year":"2012","journal-title":"Can J Ophthalmol"},{"issue":"1","key":"eoi260012r33","doi-asserted-by":"publisher","first-page":"7597","DOI":"10.1038\/s41598-023-34128-5","article-title":"Risk analysis for patients with arterial thromboembolic events after intravitreal ranibizumab or aflibercept injections.","volume":"13","author":"Chou","year":"2023","journal-title":"Sci Rep"},{"key":"eoi260012r34","volume-title":"ASRS 2025 Preferences and Trends Membership Survey","author":"Hahn","year":"2025"},{"key":"eoi260012r28","unstructured":"TriNetX. Best practices in querying global data. Accessed October 26, 2025. https:\/\/support.trinetx.com\/hc\/en-us\/article_attachments\/30502470586651"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2846904\/jamaophthalmology_bordbar_2026_oi_260012_1778698672.51491.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:00:54Z","timestamp":1779375654000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2846904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2026.0460","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}